Raised serum transaminases during treatment with pegylated interferon for chronic hepatiti C by Mandalou, P. et al.
Research Article
Clinical Microbiology and Infectious Diseases
Clin Microbiol Infect Dis, 2016         doi: 10.15761/CMID.1000116  Volume 1(3): 73-77
ISSN: 2398-8096
Raised serum transaminases during treatment with 
pegylated interferon for chronic hepatitis C
Mandalou P, Spence E, Datta S, and Mills PR*
Gastroenterology Units, Gartnavel General Hospital and Victoria Infirmary, Glasgow, UK
Abstract
Introduction: Serum transaminases rose significantly in 7 patients with chronic hepatitis C, genotypes 2 and 3, who were treated with pegylated interferon and 
ribavirin. 
Methods: 219 patients with chronic hepatitis C, genotypes 2 and 3, were treated between 2005 and 2011 following the same protocol. For the 7 patients presented in 
this paper, the initial liver screen revealed chronic hepatitis C infection only. The same liver screen was repeated following the transaminase rise during the treatment 
period and failed to reveal additional comorbidity.
Results: 5 male and 2 female patients with chronic hepatitis C experienced a rise in serum transaminases after commencement on treatment with pegylated interferon 
and ribavirin. They all achieved rapid and end of treatment virological responses. 3 of the patients achieved sustained virological response and 4 relapsed. There 
was no evidence to suggest that steatosis, development of autoimmunity or intercurrent illness was the cause of the liver injury. In 3 out of 7 patients, the level of 
transaminases exhibited a downward trend after pegylated interferon was changed to non pegylated interferon. Additionally, it is evident that in those patients whose 
treatment was temporarily or permanently aborted, the rise in transaminases rapidly improved and returned to baseline. 
Conclusion: Our experience suggests the possibility of a toxic reaction to polyethylene glycol in a small number of patients being treated with pegylated interferon, 
resulting in an acute hepatitic response which resolved when therapy was stopped or switched to non-pegylated interferon. 
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Introduction
Hepatitis C (HCV) infection is a major public health problem, 
affecting 3% of the world’s population [1]. The infection persists in 
up to 85% of patients and may result in cirrhosis and hepatocellular 
carcinoma. Since 1999, the current standard therapy consists of 
combination therapy of pegylated interferon and ribavirin with 
sustained virological response (SVR) rates ranging between 42-82% 
depending on the viral genotype [2]. Viral kinetic studies reveal that 
most patients with chronic hepatitis C (HCV) infection who achieve an 
SVR following standard treatment, clear HCV from serum within a few 
weeks [3,4]. This pattern of response to antiviral treatment is usually 
associated with a prompt reduction in elevated serum transaminases 
to normal. 
The use of this combination of drugs is associated with a variety of 
side effects, including, occasionally, elevation of serum transaminases, 
which are rarely severe. Mild rises may reflect ongoing viral activity 
in treatment non-responders. More significant rises are infrequently 
observed despite a virological response and may be due to an immuno 
modulating effect of interferon, induction of steatohepatitis [5], direct 
toxicity in susceptible patients [6,7] and intercurrent illness.
In this report, we present 7 patients with chronic hepatitis C, 
genotypes 2 and 3, whose serum transaminases rose 1.5-14 x baseline 
during treatment with pegylated interferon α2a or α2b and ribavirin 
despite all achieving a rapid viral response and end of treatment 
response. In 3 out of 7 patients, the level of transaminases exhibited 
a downward trend after pegylated interferon was changed to non-
pegylated interferon. It is also evident that in those patients whose 
treatment was temporarily or permanently aborted, their transaminases 
rapidly improved and returned to baseline.
Patient management summary
Between 2005 and 2011, a total of 219 patients with chronic 
hepatitis C, genotypes 2&3, were treated at Gartnavel General Hospital 
following the same protocol. 6 (2.8%) of these patients developed a 
hepatitic reaction during therapy and an additional patient was treated 
at the Victoria Infirmary. Prior to commencement on treatment, a full 
liver screen was performed in order to exclude co morbidities. That 
included full blood count, ferritin, coagulation profile, renal function 
indices, liver function tests (LFT), alpha-fetoprotein, caeruroplasmin, 
α1-antitrypsin, immunoglobulins, autoantibodies (ANA, AMA, SMA, 
anti-LKM, ANCA screen), hepatitis A, B, C, E, HIV antibodies, HCV 
RNA viral load and genotype and where indicated HBV DNA. Liver 
ultrasound was carried out in all patients. For the 7 patients presented 
in this report, the initial liver screen revealed chronic hepatitis C 
infection only. The same liver screen was repeated following the serum 
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transaminase rise during treatment and failed to reveal additional 
comorbidities. The results are summarised in Table 1.
Case 1
In 2004, a 50 year old Caucasian man was found by chance to 
be hepatitis C positive with genotype 2b and the only risk factor for 
acquisition that was identified was a tendon repair in Saudi Arabia 15 
years prior to presentation. He led a healthy lifestyle and did not abuse 
alcohol. He was systemically well and did not have cirrhosis. 
He was commenced on treatment in October 2005 with pegylated 
interferon α2a (Pegasys, Roche) 180μgm weekly and ribavirin 800mg 
daily for 24 weeks. At the outset of treatment AST was 95 U/L, ALT 
52 U/L, GGT 37 U/L, Alk Phos 207 U/L and bilirubin 10 μmol/L. His 
transaminases started rising 2 weeks after commencement on treatment 
and reached a peak 22 weeks later with an AST of 668 U/L, ALT 398 
U/L, GGT 541 U/L, Alk Phos 386 U/L and bilirubin 18 μmol/L (Figure 
1). He achieved a rapid virological response and therapy was continued 
for 24 weeks while monitoring the LFT.
He remained well throughout the period of treatment and his LFT 
returned rapidly to normal 2 months after cessation of treatment. He 
achieved an end of treatment response and SVR.
Case 2
In 2007, a 42 year old man of Pakistani origin, was diagnosed with 
hepatitis C, genotype 3, following investigation of abnormal LFT. 
The only risk factor for acquiring hepatitis C that was identified was 
multiple therapeutic inoculations in Pakistan as a child. He had been 
vaccinated for hepatitis B and was teetotal. His LFT at presentation 
were AST of 99 U/L, ALT 116 U/L, GGT 54 U/L and Alk Phos 65 U/L 
and he had already developed cirrhosis.
 He was commenced on treatment in March 2008 with pegylated 
interferon α2a 180mcg once weekly and ribavirin 800 mg daily and was 
HCV RNA negative at week 4, at which point his liver function started 
deteriorating and the patient developed general malaise and nausea. 
As a result, the dose of interferon was reduced at week 8 to 90 mcg. At 
week 9, treatment was stopped, as ALT rose to 423 U/L, AST to 435 
U/L and GGT to 485 U/L (Figure 2). His bilirubin was 19 μmol/L and 
Alk Phos 103 U/L.
6 weeks later, his liver function tests slowly improved, but ALT 
was still 2 and a half times the pre- treatment level and his symptoms 
resolved. 9 months after the treatment had stopped, AST dropped 
to 132 U/L, ALT to 150 U/L, GGT to 98 U/L but he was HCV RNA 
positive again.
He was offered further treatment in August 2009 with pegylated 
interferon α2a weekly and ribavirin daily after his liver function 
returned to baseline, with ALT of 144 U/L, AST 120 U/L, bilirubin 19 
μmol/L. However, he had to stop again at 8 weeks following a rise of 
AST to 404 U/L, ALT to 364 U/L, GGT to 329 U/L and recurrence of 
symptoms. Again, he achieved rapid virological and end of treatment 
response.
At this stage he was referred to our clinic for consideration of 
further treatment options. His LFT returned to baseline 4 months 
following discontinuation of treatment, but his HCV RNA was again 
positive. Further antiviral treatment was attempted in June 2010 and at 
that time his AST was 131 U/L, ALT 131 U/L, GGT 91 U/L, Alk Phos 
91 U/L and bilirubin 15 μmol/L. On this occasion, pegylated interferon 
α2b (Viraferon PEG, Schering-Plough) was used instead of α2a at a 
dose of 1.5 mcg/kg weekly and ribavirin 1000mg daily with a view to 
treating for 48 weeks. He had a rapid virological response and was 
PCR negative at 12 weeks. During this attempt, the LFT progressively 
deteriorated again and at week 12 his treatment was changed to non-
pegylated interferon α2a (Roferon A, Roche) in addition to ribavirin. 4 
weeks later, the transaminases started improving and at the end of 48 
weeks of treatment in May 2011, they returned to baseline and his HCV 
RNA was negative (Figure 3). Unfortunately, he relapsed at 6 months 
following cessation of the last treatment attempt.
Case 3
In May 2009, a 41 year old male of Pakistani origin was diagnosed 
with hepatitis C, genotype 3. He had a past medical history of jaundice 
Case Gender Age Ethnicity
(Asian/
Caucasian)
Cirrhosis Genotype Pre-treatment 
ALT (U/L)
Peak ALT
(U/L)
Start of ALT rise 
(weeks)
Duration of 
therapy (weeks)
PEG IFN
α2a or α2b
Switch to non-
PEG IFN α2a
Outcome
(RVR, EVR, EOTR, 
SVR)
1 M 50 Caucasian No 2b 52 398 2 24 α2a No RVR, EOTR, SVR
2 M 42 Asian No 3 116 364 4 9 α2a No RVR, EOTR, no SVR
144 404 2 8 α2a No RVR, EOTR, no SVR
131 310 2 48 α2b Yes RVR, EOTR, no SVR
3 M 41 Asian Yes 3 170 473 4 48 α2a Yes RVR, EOTR, no SVR 
4 M 48 Caucasian Yes 3 29 401 2 24 α2a Yes RVR, EOTR, no SVR
5 M 47 Caucasian No 2a 39 123 8 24 α2a No RVR, EOTR, no SVR
6 F 45 Caucasian Yes 3 111 187 4 7 α2a No RVR, SVR
7 F 34 Asian No 3 209 368 4 16 α2a No RVR, EOTR,SVR
Table 1. Response to pegylated interferon & ribavirin in the seven patients with chronic hepatitis C.
 
Figure 1. Case 1, treatment with Peg IFN α2a and ribavirin for 24 weeks.
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as a child of unknown cause and had been vaccinated against hepatitis 
B, following his mother’s death from hepatitis C infection. He consumes 
less than a unit of alcohol per week. His baseline LFTs were deranged, 
with a bilirubin of 29 μmol/L, AST 146 U/L, ALT 227 U/L, GGT 61 U/L, 
Alk Phos 58 U/L. Anti-HBs was positive. Immunoglobulins showed 
IgG 19.3 g/L, IgA 1.63 g/L and IgM 0.83 g/L. He had cirrhosis, portal 
hypertension, oesophageal varices and a platelet count of 77 × 109/L
He was started on pegylated interferon α2a 180mcg weekly and 
ribavirin 800mg daily in December 2010 with a plan to continue 
therapy for 48 weeks. Almost immediately after the onset of treatment, 
he developed a marked rise in serum transaminases and at week 12, his 
AST was 330 U/L, AST 473 U/L, bilirubin 52μmol/L, GGT 203 U/L and 
Alk Phos 77U/L (Figure 4). He remained asymptomatic. Repeat liver 
screening only showed a raised IgG level the titre of which was similar 
to the baseline (20.3 g/L).
 At that point, his interferon was changed to non-pegylated 
interferon α2a (Roferon A, Roche) with subsequent improvement in 
serum transaminases. At the end of treatment in November 2011, AST 
was 60/L, ALT was 58 U/L, GGT was 50 U/L, Alk Phos 73U/L and 
bilirubin 72 μmol/L. He was HCV RNA negative at weeks 12, 24 and 48 
but relapsed at the 6 month post treatment test.
Case 4
In February 2011, a 48 year old Caucasian man was referred for 
consideration of treatment for hepatitis C genotype 3 which was 
diagnosed in 2009. He had injected drugs for approximately 30 years 
but had been abstinent for 5 years prior to presentation. He did not 
abuse alcohol. He had developed cirrhosis with portal hypertension. 
His baseline LFT was as follows: AST 54 U/L, ALT 29 U/L, Alk Phos 
117 U/L and bilirubin 7 μmol/L. 
He was commenced on treatment with pegylated interferon α2a 
weekly and ribavirin daily in August 2011. 2 weeks after initiation of 
treatment, his liver function deteriorated rapidly and reached a peak at 
week 8. AST rose to 554 U/L, ALT to 322 U/L, Alk Phos to 136 U/L, and 
bilirubin was 7 μmol/L (Figure 5). Despite the rise in transaminases, he 
appeared to tolerate treatment well. 
At week 13, his interferon was changed to a non-pegylated 
interferon α2a (Roferon A, Roche). At week 24, his AST was 45 U/L, 
ALT was 20 U/L, Alk Phos 82 U/L and bilirubin 3 μmol/L. He had a 
rapid virolological response and completed 24 weeks of therapy with 
an end of treatment response. However, he relapsed at the 6 month 
post treatment test.
 
Figure 2. Case 2, first treatment attempt with Peg IFN α2a & Ribavirin for 9 weeks.
 
Figure 3. Case 2, treatment with Peg IFN α2b & Ribavirin, followed by treatment with 
non-Peg IFN α2a & Ribavirin in total for 48 weeks.
Figure 4. Case 3, treatment with Peg IFN α2a and Ribavirin followed by treatment with 
non-Peg IFN α2a and Ribavirin in total for 48 weeks.
 
Figure 5. Case 4, treatment with Peg IFN α2a and Ribavirin followed by treatment with 
non-Peg IFN α2a and Ribavirin in total for 24 weeks.
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Case 5
A 47 year old Caucasian man was diagnosed with chronic hepatitis 
C genotype 2 infection in 2001, the origin being blood transfusion in 
1975. Liver biopsy in 2001 showed chronic hepatitis with a mild to 
moderate activity without fibrosis. 
He was started on treatment in August 2005 with pegylated 
interferon α2a 180mcg per week and 800mg ribavirin daily for 24 
weeks. His AST at that time was 30 U/L, ALT 30 U/L, GGT 71 U/L, Alk 
Phos 134 U/L, bilirubin 12 μmol/L. At week 8 of treatment, his liver 
function started deteriorating and at week 14 AST rose to 63 U/L, ALT 
to 118 U/L, GGT to 216 U/L with the rest of the liver function markers 
within normal limits. He achieved a rapid virological response. He was 
merely observed as he remained asymptomatic and gradually his liver 
function normalised. At the end of treatment in January 2006, he was 
HCV RNA negative. However, he relapsed at 6 months.
Case 6
In May 2010, a 45 year old Caucasian lady, who used to inject drugs, 
was diagnosed with hepatitis C genotype 3. She smoke approximately 
twenty cigarettes per day and drank very little alcohol. Her abdominal 
ultrasound showed fatty infiltration of the liver but no evidence of 
cirrhosis or portal hypertension. The serum HCV RNA showed a viral 
load less than 1000 U/L. The patient was very keen to be started on 
treatment which was commenced in August 2010. Prior to the onset of 
therapy, AST was 99 U/L, ALT 111 U/L, GGT 275 U/L, Alk Phos 111 
U/L and bilirubin 8 μmol/L. 
She received pegylated interferon α2a and ribavirin for 7 weeks 
until mid-October 2010 when the treatment was discontinued due to 
deterioration in her LFT which started rising almost immediately after 
treatment commenced. At that time, AST was 261 U/L, ALT 177 U/L, 
GGT 912 U/L, Alk Phos 244 U/L, and bilirubin 15 μmol/L. Her HCV 
RNA was negative at week 4 and at the end of treatment.
She was then seen again in March 2011. By that stage, her LFT 
had normalised with an AST of 34 U/L, ALT 28 U/L, GGT 133 U/L, 
bilirubin 8 μmol/L and Alk Phos 124 U/L. She remained HCV RNA 
negative. However, she underwent a fibroscan which was suggestive 
of cirrhosis.
Case 7
In July 2011, a 34 year old lady of Pakistani origin was diagnosed 
with chronic hepatitis C, genotype 3 infection. She had been living 
in the UK for 6 years prior to presentation and no risk factor for 
acquisition of hepatitis C could be identified. She was a non-smoker 
and did not abuse alcohol. She underwent a fibroscan which was in 
keeping with moderate fibrosis. 
She was commenced on treatment with pegylated interferon α2a 
and ribavirin in October 2011. Her baseline LFT was abnormal with 
an ALT of 209 U/L, AST 126 U/L, Alk Phos 90 U/L and bilirubin 9 
μmol/L. 8 weeks into treatment her liver function markers deteriorated 
despite having achieved a rapid virological response. She remained well 
but her LFT continued to rise and as a result treatment was aborted 
at week 16 when AST was 209 U/L, ALT 266 U/L, Alk phos 109 U/L 
and bilirubin 8 μmol/L . The repeat liver screen revealed a polyclonic 
rise in the immunoglobulins (IgG 24.40 g/L, IgM 2.76 g/L, IgA 3.32 
g/L) but specific autoantibody tests were negative. Her liver function 
tests gradually improved and returned to baseline 6 weeks after the 
treatment was stopped. She achieved SVR and remains well.
Discussion
Seven patients with chronic hepatitis C are presented who 
sustained rapid and significant rises in serum transaminases during 
therapy with pegylated interferon α2a and ribavirin despite a rapid and 
end of treatment virological response. Three of the patients achieved 
sustained virological response and four relapsed. Interestingly, they 
all had non genotype 1 infection. Intercurrent illness, reactivation of 
hepatitis B and autoimmune hepatitis were excluded as possible causes.
During treatment with pegylated interferon, significant serum 
transaminase elevations above baseline are not common but are 
occasionally clinically significant. This biochemical response has been 
little studied. The transaminase elevations that occurred in 35% of 
patients treated with pegylated interferon and ribavirin for chronic 
HCV infection between October 2000 and October 2003 [5]. Most 
commonly, minor rises (< 1.5x baseline) occurred early in the course 
of treatment and were associated with failure to achieve a virological 
response. More significant transaminase elevations (>1.5x baseline) 
were observed later in the course of treatment and were associated with 
similar virological response rates to patients who did not experience 
toxicity. On univariate and multivariate analysis, increased body 
weight and increased severity of steatosis on pre-treatment liver biopsy 
were associated with transaminase elevations. Steatosis is a common 
finding in patients with chronic hepatitis C [8], and the pathogenesis is 
multifactorial. A causative role for HCV in the development of steatosis 
is supported by the observation that it occurs more commonly with 
HCV genotype 3 infections and improves after viral eradication [5]. 
Even though 2 of the patients presented in this paper had hypertension 
and diabetes, there was not enough biochemical or other evidence 
to suggest that non-alcoholic fatty liver disease contributed to the 
sustained liver injury.
Interferon has several antiviral mechanisms, but its role in hepatitis 
C seems to be related to its immunomodulatory effect [9]. Interferon 
therapy for patients with hepatitis C infection has been reported to 
induce or exacerbate autoimmune hepatitis [10,11]. Kogure et al. [12] 
have reported fulminant hepatic failure secondary to autoimmune 
hepatitis with development of anti LKM-1 and ANA antibodies that 
was confirmed on liver biopsy following a 12 week course of treatment 
with pegylated interferon alpha-2b for chronic hepatitis C (1a genotype) 
[12]. One of the explanations for the occurrence of autoimmunity in 
HCV patients is the loss of self-tolerance due to molecular mimicry 
between viral proteins and self-antigen [13]. Merli et al. [14] have 
reported development of de novo autoimmune hepatitis in patients 
who had HCV infected liver grafts (genotypes 1a & 1b) and received 
treatment with pegylated interferon and ribavirin [14]. Parana et al. 
[15] reported the development of anti-Golgi complex and progression 
of liver disease in 3 patients during pegylated interferon treatment for 
HCV infection (genotypes 1a). In this study it was suggested that a 
rise in transaminases could be secondary to temporary autoimmune 
phenomenon triggered by treatment, however the lack of histological 
confirmation raised the question of hepatotoxicity of pegylated 
interferon α2a. In our own cases, autoantibody markers were at all 
times negative, which is against this hypothesis.
Caroleo et al. [7] have reported an increase in serum transaminase 
levels 4 months after the start of pegylated interferon α2a treatment 
for chronic hepatitis C (genotype 1b) secondary to a possible direct 
toxic effect as seen on immunostaining following liver biopsy. In 
contrast, transaminases normalised following change of treatment 
to pegylated interferon α2b as shown in the same case report [7]. It 
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was postulated that because of the molecular weight of the PEG chain 
of pegylated interferon α2a (40 kDa), it accumulates in the liver, has 
higher distribution in plasma volume and its half-life is approximately 
twice that of pegylated interferon α2b. Therefore, pegylated interferon 
α2a is able to accumulate in tissues such as liver which have high 
plasma volumes. In our report, the use of pegylated interferon α2b did 
not result in normalisation of transaminases, which was achieved only 
when switched to non-pegylated interferon α2a.
Mishra et al. [6] have reported a marked rise in transaminases with 
both pegylated forms of interferon [6], raising the question of toxicity 
secondary to polyethylene glycol. PEGylation provides benefits that are 
derived from the covalent attachment of polyethylene glycol (PEG), a 
synthetic polymer of ethylene oxide, to bioactive species. When PEG 
is attached to the surface of a protein, the resulting increase in size 
reduces renal clearance and increases stability by enhancing resistance 
to proteolysis, which prolongs protein circulating times [16]. PEGs, 
however, contain potential impurities such as ethylene oxide and 1,4 
dioxane which are toxic. In 3 of the cases, the levels of the liver enzymes 
exhibited a downward trend once pegylated interferon was changed 
to non-pegylated interferon α. Additionally, it is evident that in those 
patients whose treatment was temporarily or permanently aborted, 
their transaminases decreased slowly to baseline.
Unfortunately, no liver biopsy was done during the hepatitic 
responses in our patients. This is a potential weakness as it is possible 
that this might have aided in the determination of the mechanism of 
this reaction and helped to rule out other conditions. However, the 
timing of the response in relation to pegylated interferon was so rapid, 
reproducible and resolved with switching to non-pegylated interferon 
or cessation of therapy as to leave no doubt as to the relationship to the 
therapy.
In summary, our report suggests the possibility of a toxic reaction 
to polyethylene glycol in 2.8% of patients being treated with pegylated 
interferon resulting in an acute hepatitic response which resolved 
when therapy was stopped or switched to non-pegylated interferon. 
It was interesting, but possibly coincidental, that this reaction only 
occurred in non-genotype 1 infection, that it was more common in 
Asian patients and that all patients had a rapid viral response and end 
of treatment response while on therapy. No other explanation for the 
acute hepatitis reaction was found in these patients despite extensive 
investigation. This rare toxic response to polyethylene glycol caused 
occasional symptoms, concern on the part of the medical teams but 
no serious illness despite 3 patients having cirrhosis. It rapidly resolves 
following cessation of therapy with no apparent longer-term sequelae.
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